High-dose vitamin C improves BCG immunotherapy's efficacy in a murine ectopic model of bladder cancer.
High-dose vitamin C (VitC) has shown promise in improving the outcome of immunotherapies such as immune checkpoint blockade.
SUNRIDGE MEDICAL • INTEGRATIVE ONCOLOGY • EVIDENCE REVIEWED SEPTEMBER 2026
High-Dose Intravenous Vitamin C (IV Ascorbate) for Cancer
IV vitamin C consultation
Find Out Whether High-Dose IV Vitamin C Fits Your Case
Eligibility depends on the diagnosis, kidney function, G6PD screening, medications and oncology schedule. Our Patient Care Team can help gather the information needed for physician review.
- G6PD and kidney-risk screening come before treatment
- Infusion timing is coordinated with oncology care
- Call now for an immediate response from our Patient Care Team
IV vitamin C consultation
Speak With Our Patient Care Team
Share your diagnosis, current treatment and questions about high-dose IV vitamin C.
* Required fields
Prefer to speak with someone now?
1-800-923-7878 - G6PD and kidney-risk screening come before treatment
- Infusion timing is coordinated with oncology care
- Questions before scheduling are always welcome
High-dose intravenous vitamin C—also called IV ascorbate, pharmacologic ascorbate or intravenous ascorbic acid—is biologically different from oral vitamin C. IV administration bypasses intestinal absorption limits and can produce millimolar blood concentrations that ordinary oral dosing cannot achieve.1, 2
At these pharmacologic concentrations, experimental research shows that ascorbate can generate hydrogen peroxide, interact with redox-active iron, alter tumor metabolism and increase oxidative stress in susceptible cancer cells.3, 4, 10
The strongest recent human signal comes from a small randomized 2024 metastatic pancreatic cancer trial. Adding 75 g IV ascorbate three times weekly to gemcitabine plus nab-paclitaxel was associated with median overall survival of 16.0 months versus 8.3 months and median progression-free survival of 6.2 versus 3.9 months, without an increase in adverse-event frequency or severity.14 The finding is promising and deserves larger independent replication.
Important: high-dose IV vitamin C remains an investigational adjunct. It is not FDA-approved to treat cancer and should not replace or delay oncology care.
On This Page
Evidence review and clinical context
Research-Forward, Physician-Directed Information
Prepared by the Sunridge Medical editorial team using primary human studies, PubMed-indexed publications and the National Cancer Institute review. Results are presented with study design, participant count and limitations so promising findings are not mistaken for guarantees.
KEY EVIDENCE AT A GLANCE
Quick Summary: What the Research Shows
IV and oral vitamin C are pharmacologically different. IV dosing can produce plasma concentrations measured in millimoles rather than the tightly controlled micromolar concentrations typical of oral dosing.2
A 2024 randomized pancreatic trial reported a large survival signal. Median OS was 16.0 vs. 8.3 months and median PFS was 6.2 vs. 3.9 months when IV ascorbate was added to gemcitabine/nab-paclitaxel.14
A 2025 meta-analysis pooled 8 studies and 2,722 adults. IV vitamin C was associated with a median overall-survival ratio of 1.83; however, the studies were heterogeneous and included both cohorts and randomized trials.18
Advanced NSCLC results were encouraging. A single-arm phase II study reported a 34.2% objective response rate and 84.2% disease-control rate with IV ascorbate plus carboplatin/paclitaxel.12
Ovarian cancer research reported less chemotherapy-related toxicity. A small randomized phase I/IIa study found fewer grade 1 and 2 adverse events when IV ascorbate was added to carboplatin/paclitaxel.8
Glioblastoma research established feasibility. A phase I study reported median PFS of 9.4 months and median OS of 18 months, but it was not a randomized efficacy trial.11
Safety screening is essential. G6PD status, kidney function, stone history, iron overload risk, fluid/electrolyte status and treatment interactions all require medical review.1
It is an adjunct, not a replacement. IV vitamin C is not FDA-approved as a cancer treatment, and evidence differs by cancer type, dose and treatment combination.
Human clinical evidence
What Human Studies Have Reported
Human research has produced several encouraging signals, particularly when high-dose intravenous vitamin C was added to standard cancer treatment. Study size and design vary, so these findings support further investigation rather than guaranteeing benefit for an individual patient.
| Study | Design and treatment | Reported findings | How to interpret it |
|---|---|---|---|
| Metastatic pancreatic cancer Randomized phase II, 2024 | 36 randomized; 34 treated. The investigational group received 75 g IV ascorbate three times weekly with gemcitabine/nab-paclitaxel. | Median OS was 16.0 vs. 8.3 months (HR 0.46; 90% CI 0.23–0.92). Median PFS was 6.2 vs. 3.9 months (HR 0.43; 90% CI 0.20–0.92). No increase in adverse-event frequency or severity was reported. | The strongest randomized positive signal to date, but it was a small phase II trial. Larger independent multicenter studies are needed.14 |
| Stage III–IV ovarian cancer Pilot randomized phase I/IIa, 2014 | 27 women were randomized. IV ascorbate, generally 75–100 g twice weekly, was added to carboplatin/paclitaxel. | The IV-ascorbate group had significantly fewer grade 1 and 2 chemotherapy-related adverse events. Median time to progression/relapse was 25.5 vs. 16.75 months, but survival analyses were not statistically significant. | The toxicity result is encouraging; the trial was too small to establish a survival benefit.8 |
| Advanced NSCLC Single-arm phase II, 2022 | 38 patients received 75 g IV ascorbate twice weekly with carboplatin/paclitaxel. Results were compared with a historical response rate. | Objective response rate was 34.2%; disease control was 84.2%; median PFS was 5.7 months and median OS was 12.8 months. | The response endpoint was met, but a single-arm design cannot isolate the contribution of IV ascorbate.12 |
| Newly diagnosed glioblastoma First-in-human phase I, 2019 | 11 evaluable patients received pharmacologic ascorbate with radiation and temozolomide. | No dose-limiting toxicities occurred. Median PFS was 9.4 months and median OS was 18 months. | This safety/dose-escalation study lacked a randomized control. Historical comparisons can suggest a signal but cannot prove efficacy.11 |
| Early pancreatic studies Phase I and I/IIa, 2012–2017 | Three small studies tested IV ascorbate with gemcitabine-based therapy, including 14, 9 and 14 enrolled patients. | They reported feasibility, no clear added toxicity, stable disease in some participants and encouraging survival observations. | These trials helped establish feasibility but were small and uncontrolled.6, 7, 20 |
| Multiple cancers Systematic review/meta-analysis, 2025 | Eight randomized or cohort studies involving 2,722 adults were pooled; cancer types, doses and combinations varied. | IV vitamin C was associated with a median OS ratio of 1.83 (95% CI 1.40–2.40). The PFS ratio was 1.80 but was not statistically significant (95% CI 0.95–3.41). | Encouraging pooled association, but heterogeneity and stronger effects in cohorts than randomized trials limit causal conclusions.18 |
Every study above links to its primary publication in the reference list. Absolute results, design limitations and the difference between randomized and single-arm evidence are shown so readers can evaluate the strength of each signal.
PHARMACOLOGIC ASCORBATE
What Is High-Dose Intravenous Vitamin C?
Vitamin C is ascorbic acid, an essential water-soluble nutrient involved in collagen synthesis, antioxidant defense, iron metabolism and multiple enzyme systems. In normal physiology, blood levels are tightly regulated. The intestine limits absorption and the kidneys rapidly excrete excess vitamin C. That is why simply taking progressively larger oral doses does not reproduce the pharmacology of an IV infusion.2
In oncology research, the term pharmacologic ascorbate usually refers to intravenous doses sufficient to produce plasma concentrations in the millimolar range. Research protocols have used many schedules—often weight-based doses around 0.6 to 1.5 g/kg or fixed doses such as 50 to 100 g per infusion. These numbers describe published research protocols; they are not a universal dosing recommendation. Dose, infusion rate, frequency, kidney function, G6PD status, hydration, electrolytes, concurrent therapy and treatment goals all require individualized medical consideration.
PHARMACOKINETICS • IV VS ORAL
Why IV Vitamin C Is Not the Same as Oral Vitamin C
This is the pharmacologic point that resolves much of the historical controversy. In a landmark human pharmacokinetic study, Padayatty and colleagues showed that oral vitamin C is subject to tight gastrointestinal and renal control, while IV administration bypasses intestinal absorption and creates far higher transient plasma concentrations.2
Modern trials frequently aim for plasma concentrations of approximately 20 millimolar or higher. In the 2024 pancreatic cancer trial, the investigators described IV ascorbate as raising serum levels from the micromolar into the millimolar range. The trial used 75 g three times weekly alongside gemcitabine and nab-paclitaxel.14
This matters because many laboratory anti-cancer effects of ascorbate occur at concentrations that ordinary oral supplementation cannot reproduce. Therefore, older trials of oral vitamin C cannot simply be treated as equivalent tests of modern high-dose IV vitamin C cancer treatment. The National Cancer Institute specifically notes that early randomized studies using 10 g/day oral vitamin C did not improve survival, while IV delivery produces substantially higher blood concentrations and is now studied as a distinct pharmacologic intervention.1
REDOX BIOLOGY • METABOLISM • SELECTIVITY
How Pharmacologic Ascorbate May Affect Cancer Cells
1. Extracellular Hydrogen Peroxide Generation
One of the best-studied mechanisms is the formation of hydrogen peroxide in extracellular fluid. NIH investigators demonstrated that pharmacologic concentrations of ascorbate could selectively kill several cancer-cell lines while leaving tested normal cells comparatively resistant. Catalase—which breaks down hydrogen peroxide—blocked much of the effect, supporting hydrogen peroxide as a central mediator.3
Follow-up in vivo work showed that parenteral ascorbate generated ascorbate radical and hydrogen peroxide in extracellular fluid but not in blood to the same degree. This led researchers to describe pharmacologic ascorbate as a prodrug for extracellular hydrogen-peroxide formation.4
2. Redox-Active Iron and Fenton Chemistry
Cancer cells frequently operate under greater baseline oxidative stress than normal cells and may contain altered pools of redox-active iron. In non-small-cell lung cancer and glioblastoma models, investigators found that pharmacologic ascorbate exploited differences in mitochondrial oxidative metabolism and labile iron. Hydrogen peroxide generated from ascorbate can react with redox-active iron through Fenton chemistry, producing highly reactive species that damage DNA, proteins and lipids.10
This model is attractive because it offers a plausible explanation for selectivity: a cancer cell already living near the limits of oxidative stress may be less able than a normal cell to buffer a sudden pharmacologic redox challenge.
3. Glycolysis, GLUT1 and GAPDH in KRAS/BRAF-Mutated Cancer
A landmark Science paper investigated KRAS- and BRAF-mutated colorectal cancer cells. These highly glycolytic cells expressed high levels of the glucose transporter GLUT1 and took up the oxidized form of vitamin C, dehydroascorbate. Reducing dehydroascorbate back to ascorbate consumed glutathione, increased oxidative stress and inactivated GAPDH, a key glycolytic enzyme. The result was ATP depletion and energetic crisis in susceptible mutant cells.9
This preclinical mechanism became especially interesting after the large VITALITY colorectal cancer trial found no overall PFS benefit in an unselected population but did identify a statistically significant PFS benefit in the prespecified RAS-mutated subgroup.13 That does not prove the mechanism clinically, but it supports the broader concept that tumor biology may determine who is most likely to benefit.
4. Mitochondrial and Metabolic Stress
Pharmacologic ascorbate has been shown in multiple experimental systems to alter mitochondrial redox balance, ATP production, glycolysis and cellular antioxidant systems. These effects are highly context dependent, which is one reason the evidence should be interpreted by cancer type rather than assuming a universal response.
5. Potential Radiosensitization
Preclinical pancreatic cancer work has shown that pharmacologic ascorbate can increase radiation sensitivity in tumor cells while reducing some radiation injury in normal tissue models. Early clinical programs have subsequently evaluated high-dose ascorbate alongside radiation and chemotherapy in glioblastoma, lung cancer and pancreatic cancer.10, 11
Mechanistic research includes hydrogen peroxide generation, redox-active iron chemistry and metabolic vulnerability.
RANDOMIZED CLINICAL DATA • 2024
The Strongest New Clinical Data: Metastatic Pancreatic Cancer
Randomized Metastatic Pancreatic Cancer Trial • 2024
16.0 mo
Median overall survival with IV ascorbate + chemotherapy
Median overall survival with IV ascorbate + chemotherapy
8.3 mo
Median overall survival with chemotherapy alone
Median overall survival with chemotherapy alone
6.2 mo
Median progression-free survival with IV ascorbate
Median progression-free survival with IV ascorbate
3.9 mo
Median progression-free survival control arm
Median progression-free survival control arm
The most important modern clinical result for IV vitamin C and cancer came from a randomized trial published in Redox Biology in 2024. Patients with stage IV pancreatic ductal adenocarcinoma were randomized to gemcitabine plus nab-paclitaxel alone or the same chemotherapy plus pharmacologic ascorbate at 75 g intravenously three times weekly.14
Thirty-six patients were randomized and 34 received assigned treatment. The results were:
- Median overall survival: 16.0 months with IV ascorbate + chemotherapy versus 8.3 months with chemotherapy alone.
- Overall-survival hazard ratio: 0.46 (90% CI 0.23–0.92; p=0.030).
- Median progression-free survival: 6.2 months versus 3.9 months.
- PFS hazard ratio: 0.43 (90% CI 0.20–0.92; p=0.029).
- Quality of life: no detected detrimental effect from adding ascorbate.
- Toxicity: the investigators reported no increase in the frequency or severity of adverse events attributable to adding pharmacologic ascorbate.
These findings are unusually encouraging for a nutrient-derived therapy studied in metastatic cancer. At the same time, the trial was relatively small. The appropriate scientific response is not to dismiss the result, nor to declare the question settled, but to recognize it as a significant randomized signal that deserves replication in larger studies.
PANCREATIC CANCER • EARLY PHASE TRIALS
Earlier Pancreatic Cancer Trials
The 2024 randomized study did not appear out of nowhere. Earlier phase I studies had already established the feasibility of combining high-dose IV ascorbate with pancreatic cancer therapy.
Monti and colleagues evaluated IV ascorbate with gemcitabine and erlotinib in metastatic pancreatic cancer. The combination was feasible and the ascorbate component produced minimal additional toxicity.6
Welsh and colleagues then studied pharmacologic ascorbate with gemcitabine in metastatic and node-positive pancreatic cancer. The trial established feasibility, reached pharmacologic plasma concentrations and provided the foundation for later randomized work.7
OVARIAN CANCER
Ovarian Cancer: Chemotherapy Tolerance and Early Efficacy Signals
In 2014, Ma and colleagues published translational and clinical data in women with stage III/IV ovarian cancer. Twenty-seven patients were randomized to carboplatin/paclitaxel alone or chemotherapy plus IV vitamin C. Vitamin C was continued beyond the chemotherapy period.8
The addition of IV vitamin C was associated with lower chemotherapy-related toxicity. The study also reported signals in disease outcomes that encouraged further study, but it was too small to establish a definitive survival benefit. The importance of this trial is that it addressed two clinically relevant questions at the same time: whether pharmacologic ascorbate could be safely combined with cytotoxic chemotherapy and whether it might improve treatment tolerability rather than simply adding another burden.
NON-SMALL CELL LUNG CANCER
Non-Small Cell Lung Cancer: Phase II Results
A 2022 phase II study evaluated pharmacologic ascorbate with carboplatin and paclitaxel in advanced-stage non-small cell lung cancer. Forty patients were enrolled and 38 were evaluable for efficacy. Ascorbate was administered at 75 g twice weekly for 12 weeks alongside four cycles of platinum-doublet chemotherapy.12
The study reported:
- Objective response rate: 34.2%, all confirmed partial responses.
- Disease-control rate: 84.2%.
- Median progression-free survival: approximately 5.7 months.
- Median overall survival: approximately 12.8 months.
The investigators concluded that the study met its primary response objective and warranted further investigation. Because it was a single-arm study rather than a randomized comparison, it cannot establish how much of the response was caused specifically by ascorbate. It is nonetheless an important example of pharmacologic ascorbate being integrated prospectively with standard chemotherapy in advanced cancer.
GLIOBLASTOMA
Glioblastoma: Pharmacologic Ascorbate With Radiation and Temozolomide
The University of Iowa group also conducted a first-in-human phase I trial in newly diagnosed glioblastoma using pharmacologic ascorbate with standard radiation and temozolomide. The combination was feasible, and doses were escalated to achieve target plasma ascorbate concentrations.11
The trial reported median progression-free survival of approximately 9.4 months and median overall survival of approximately 18 months. These results compared favorably with historical expectations, but the study was small and nonrandomized, so they should be considered hypothesis-generating rather than proof of a survival advantage.
COLORECTAL CANCER • BIOMARKER SIGNAL
Colorectal Cancer: A Large Phase III Trial and a Biomarker Signal
The VITALITY study is important because it prevents an overly simplistic story. This randomized, open-label, multicenter phase III trial enrolled more than 400 patients with previously untreated metastatic colorectal cancer and compared FOLFOX with or without bevacizumab against the same regimen plus high-dose IV vitamin C.13
In the overall study population, high-dose vitamin C did not significantly improve progression-free survival. Median PFS was approximately 8.6 versus 8.3 months. Overall survival and objective response were also similar.
However, a prespecified subgroup analysis produced a notable finding: patients whose tumors carried RAS mutations had median PFS of approximately 9.2 months with vitamin C versus 7.8 months without it (HR 0.67; 95% CI 0.50–0.91). This is particularly interesting in light of the preclinical KRAS/BRAF-GLUT1-GAPDH mechanism described by Yun and colleagues.9, 13
The lesson is not that every colorectal cancer patient should receive vitamin C. It is that a biologically selected subgroup may behave differently from an unselected population—exactly the type of question modern precision oncology is designed to investigate.
Personalized IV vitamin C review
Discuss the Evidence in the Context of Your Diagnosis
The relevance of published research depends on the cancer type, stage, current oncology regimen, kidney function, G6PD status and treatment goals. Our Patient Care Team can organize the information needed for physician review.
- Evidence and safety screening reviewed together
- Timing coordinated with the oncology treatment plan
- Formulation and ingredient source documented
High-dose IV vitamin C consultation
Speak With Our Patient Care Team
Share your diagnosis, current treatment and questions. This is the same secure website inquiry form used throughout Sunridge Medical.
* Required fields
Prefer to speak with someone now?
1-800-923-7878 - G6PD and kidney-risk screening come before treatment
- Infusion timing is coordinated with oncology care
- Questions before scheduling are always welcome
PROSTATE CANCER • NEGATIVE RANDOMIZED DATA
Prostate Cancer: Why Negative Trials Matter
A 2024 randomized placebo-controlled phase II trial examined high-dose IV vitamin C with docetaxel in men with metastatic castration-resistant prostate cancer. The addition of IV vitamin C did not improve PSA response, toxicity or other clinical outcomes.15
This result belongs on a serious page about vitamin C cancer treatment because it shows that pharmacologic ascorbate is not universally effective. Tumor type, redox biology, genetic context, treatment partner, dose, schedule and disease stage may all influence whether the therapy adds value.
QUALITY OF LIFE • SUPPORTIVE ONCOLOGY
Can IV Vitamin C Improve Quality of Life During Cancer Treatment?
The National Cancer Institute notes studies reporting improved quality of life and reductions in cancer-related toxicities with IV vitamin C.1 Patients in integrative oncology commonly seek IV ascorbate not only for a potential direct anti-cancer effect but also because treatment burden, fatigue, appetite, pain, sleep and functional capacity matter enormously during a long cancer course.
However, supportive-care benefits should be evaluated with the same discipline as anti-tumor claims. Quality-of-life outcomes can be influenced by many factors, and not every study uses a blinded randomized design. The strongest approach is to define what is being targeted and then monitor whether the patient is actually improving.
IV ascorbate has been studied both for potential anti-tumor activity and for supportive-care outcomes.
CHEMOTHERAPY COMBINATIONS
IV Vitamin C With Chemotherapy
The interaction between antioxidants and chemotherapy is often discussed too broadly. Pharmacologic IV ascorbate should not simply be equated with ordinary antioxidant supplementation. At millimolar concentrations it can create pro-oxidant effects, and multiple clinical trials have combined it with chemotherapy.
Examples include:
- Gemcitabine ± erlotinib in pancreatic cancer.6, 7
- Carboplatin/paclitaxel in ovarian cancer.8
- Carboplatin/paclitaxel in advanced NSCLC.12
- FOLFOX ± bevacizumab in metastatic colorectal cancer.13
- Gemcitabine/nab-paclitaxel in metastatic pancreatic cancer.14
- Docetaxel in metastatic castration-resistant prostate cancer.15
These studies make it clear that interaction questions should be answered drug by drug and protocol by protocol. The National Cancer Institute also notes preclinical concerns with some agents, including bortezomib, so coordination with the oncology treatment plan remains important.1
RADIATION COMBINATIONS
IV Vitamin C With Radiation
Radiation kills cancer partly through oxidative injury, making redox-modifying therapies an important area of research. Pharmacologic ascorbate has demonstrated radiosensitizing effects in several tumor models. Early human work in glioblastoma has shown that IV ascorbate can be administered with radiation and temozolomide.10, 11
Whether ascorbate should be given on the same day as radiation, how close to treatment, and at what dose are protocol-level questions. Timing should be determined medically rather than assumed from the word “antioxidant.”
IMMUNOTHERAPY RESEARCH
What About Immunotherapy?
Vitamin C has immunologic and epigenetic effects at physiologic concentrations, and preclinical studies continue to explore possible synergy between high-dose ascorbate and immune-checkpoint therapy. Human evidence is still much less developed than the chemotherapy literature. It is reasonable to describe this as an active research area, not an established indication.
DOSE • FREQUENCY • PLASMA TARGETS
How High Are the Doses Used in Cancer Research?
Research protocols vary substantially. Published studies have used fixed doses such as 50 g, 75 g or 100 g per infusion and weight-based doses up to approximately 1.5 g/kg. Some protocols infuse ascorbate two or three times weekly; others coordinate it around chemotherapy cycles.
The target in many pharmacologic-ascorbate programs is not merely a gram amount but a plasma concentration. Several trials have sought concentrations around or above 20 mM. That is another reason an IV vitamin C cancer program should be treated as a medical therapy rather than as a routine wellness infusion.
Clinical status: High-dose IV vitamin C is not FDA-approved as a cancer treatment. It is studied and used as an adjunct—not as a replacement for surgery, radiation, immunotherapy, chemotherapy, targeted therapy or other oncology care. It should never be used to delay treatment recommended by a patient’s oncology team. Screening for G6PD deficiency, kidney/stone risk, iron overload, fluid and electrolyte needs, glucose-meter interference and regimen-specific interactions is essential.1
G6PD • RENAL FUNCTION • CLINICAL SCREENING
Safety: Who Needs Careful Screening?
G6PD Deficiency
Kidney Function and Oxalate
Vitamin C can be metabolized to oxalate. Kidney impairment, dehydration, prior oxalate stones and other renal risk factors deserve careful evaluation. The National Cancer Institute specifically identifies renal disease and urolithiasis as important risk factors when considering high-dose IV ascorbate.1
Point-of-Care Glucose Testing
Very high circulating ascorbate concentrations can interfere with some finger-stick glucose meters and produce misleading glucose readings. The 2024 pancreatic randomized trial specifically addressed this issue in its eligibility and monitoring procedures.14
Fluid, Electrolytes and Infusion Tolerance
Infusion volume, sodium load, hydration status, blood pressure, electrolytes and overall cardiovascular/renal condition should be considered. Temporary thirst, increased urination, nausea, chills and other infusion-related effects have been reported in clinical studies.1
Medication and Treatment Interactions
Every medication and cancer treatment should be reviewed. Concerns about interactions should not be addressed by a blanket “antioxidants are bad with chemotherapy” rule, but neither should they be ignored. A pharmacologic intervention capable of altering redox biology deserves treatment-specific interaction review.
PHYSICIAN-DIRECTED MONITORING
What Monitoring May Be Considered?
The exact laboratory plan depends on the patient, cancer and treatment combination, but physician-directed programs may consider:
- G6PD status before initiating high-dose treatment.
- Kidney function and metabolic panel.
- Hydration and electrolyte status.
- Stone history and relevant renal risk.
- CBC when the patient is receiving myelosuppressive treatment.
- Concurrent medications and chemotherapy schedule.
- Clinical symptoms and treatment tolerance.
- Imaging and tumor markers when they are appropriate to the underlying cancer.
CANCER-SPECIFIC EVIDENCE
Which Cancer Types Have Been Studied?
Clinical or substantial preclinical research has evaluated pharmacologic ascorbate in pancreatic cancer, ovarian cancer, colorectal cancer, non-small cell lung cancer, glioblastoma, prostate cancer, gastric cancer and several other malignancies. Laboratory studies extend across an even broader range of tumor types.
That does not mean the evidence is equally strong for every diagnosis. A useful hierarchy is:
- Randomized human evidence for the specific cancer and treatment combination.
- Prospective nonrandomized human evidence.
- Case-series and observational evidence.
- Animal evidence.
- Cell-culture and mechanistic evidence.
A biologically attractive mechanism should generate a clinical hypothesis; it should not be mistaken for a completed clinical trial.
PATIENT SELECTION
What Makes a Patient a Potential Candidate?
There is no single profile that automatically makes someone a candidate for IV vitamin C. A meaningful evaluation asks:
- What is the cancer type, stage and current disease burden?
- What pathology and molecular information is available?
- What treatments have already been used and how did the cancer respond?
- Is the patient currently receiving chemotherapy, radiation, immunotherapy or targeted therapy?
- What clinical goal is being pursued—tumor response, treatment support, symptom improvement, or another objective?
- Are kidney function and G6PD status appropriate?
- Could the therapy interact with the current regimen?
- How will the treatment be reassessed?
The Sunridge formulation
Preservative-Free IV Ascorbic Acid With Transparent Sourcing
At Sunridge Medical, IV ascorbic acid is compounded in our compounding laboratory as a preservative-free preparation. We select a verified non-corn starting material—generally beet- or tapioca-derived, depending on the manufacturer and ingredient lot—and document the source used for the preparation.
Compounded in-housePrepared in the Sunridge Medical compounding laboratory under physician direction.
Preservative-freeFormulated without added preservatives for a transparent high-dose infusion protocol.
Verified non-corn sourceGenerally beet- or tapioca-derived, with the current manufacturer and lot documented.
What this does—and does not—mean: this sourcing choice reflects Sunridge Medical’s formulation-transparency standard. It does not establish that non-corn, beet-derived, tapioca-derived or preservative-free IV ascorbate produces better tumor response, longer survival or greater overall safety. Comparative human trials have not demonstrated those advantages.
SUNRIDGE MEDICAL • INTEGRATIVE ONCOLOGY
How Sunridge Medical Approaches IV Vitamin C Cancer Treatment
At Sunridge Medical, the question is not simply whether high-dose IV vitamin C has research behind it. The clinically useful question is whether the evidence, safety profile and treatment timing make sense for the individual patient, individual cancer and current oncology plan.
A physician-directed evaluation may consider diagnosis, stage, pathology, molecular findings, previous therapies, current regimen, blood counts, kidney function, G6PD status, stone and iron-overload risk, treatment tolerance and patient goals. IV ascorbate can then be considered as one component of a broader integrative strategy rather than a generic protocol.
Sunridge also compounds its own preservative-free IV ascorbic acid from a verified non-corn starting source, generally beet- or tapioca-derived depending on the ingredient lot. That sourcing is disclosed for formulation transparency; it is not presented as proof of superior anticancer effectiveness.
IV vitamin C, vitamin D and Epstein–Barr virus
What the Published EBV Study Found
A 2014 retrospective clinic-record analysis examined IV vitamin C doses from 7.5 to 50 g. The database included 178 patients with elevated EBV early-antigen IgG and 40 with elevated viral-capsid-antigen IgM; detailed before-and-after information was available for 35 patients.
Among those 35 patients, mean EBV early-antigen IgG decreased from 80±55 to 46±43 AU (p=0.001); 32 patients had a decrease and 3 had an increase. Plasma ascorbate was inversely associated with EBV VCA IgM, and higher vitamin D levels were associated with lower EBV early-antigen IgG.19
Important limitation: this was retrospective—not a randomized trial and not a cancer-treatment study. It did not establish that IV vitamin C or vitamin D clears EBV, prevents EBV-associated disease or cures chronic symptoms. Antibody levels are not the same as a direct viral-load measurement. The findings are hypothesis-generating and require controlled confirmation.
FREQUENTLY ASKED QUESTIONS
Frequently Asked Questions About Vitamin C and Cancer
Can oral vitamin C achieve the same concentrations as IV vitamin C?
No. Human pharmacokinetic data show that IV administration can create plasma concentrations many times higher than oral administration. This is why pharmacologic-ascorbate cancer studies use intravenous delivery.
Has IV vitamin C improved survival in a randomized cancer trial?
A small 2024 randomized metastatic pancreatic cancer trial reported median overall survival of 16.0 months with IV ascorbate plus gemcitabine/nab-paclitaxel versus 8.3 months with chemotherapy alone, and median progression-free survival of 6.2 versus 3.9 months. The result is promising and needs larger independent replication.
Is high-dose IV vitamin C FDA-approved to treat cancer?
No. High-dose IV vitamin C is investigational as a cancer treatment. It may be considered as a physician-directed adjunct in selected cases, but it should not replace or delay standard oncology care.
Can IV vitamin C be used with chemotherapy?
Human trials have combined pharmacologic ascorbate with several chemotherapy regimens. Whether it is appropriate depends on the drugs, cancer type, dose, timing, kidney function, G6PD status and other patient factors. The oncology and infusion teams should coordinate the plan.
Is IV vitamin C safe?
Clinical trials generally report good tolerability in appropriately screened patients, but serious risk can exist with G6PD deficiency, significant kidney disease or stone risk, iron overload and other clinical conditions. High circulating ascorbate can also interfere with some point-of-care glucose meters.
Does high-dose IV vitamin C work for every cancer?
No. Findings vary by cancer type, treatment combination and study design. Positive results in one cancer cannot be assumed to apply to another, which is why the diagnosis and evidence must be reviewed individually.
Why does Sunridge use preservative-free, non-corn IV ascorbic acid?
Sunridge compounds a preservative-free preparation using a verified non-corn starting source, generally beet- or tapioca-derived depending on the manufacturer and lot. This provides formulation transparency, but comparative human trials have not shown that this sourcing produces better cancer outcomes.
What did the published IV vitamin C and EBV study report?
A 2014 retrospective clinic-record analysis reported reductions in EBV antibody levels during IV vitamin C therapy and correlations involving plasma ascorbate and vitamin D. It was not randomized, did not measure cure, and cannot establish that IV vitamin C or vitamin D clears EBV.
Is the goal always to shrink the tumor?
No. Depending on the case and evidence, a physician may be evaluating treatment tolerance, symptom burden, quality of life, biologic response or antitumor activity. The objective should be defined before treatment and reassessed over time.
EVIDENCE SUMMARY
Bottom Line
The modern evidence for vitamin C cancer treatment is more sophisticated than either extreme of the debate suggests. High-dose intravenous vitamin C is pharmacologically different from oral supplementation; it reaches millimolar plasma concentrations, has well-described pro-oxidant and metabolic effects in experimental cancer systems, and has been safely integrated with several conventional cancer therapies in human trials.
The most compelling recent result is the 2024 randomized metastatic pancreatic cancer study, where adding 75 g IV pharmacologic ascorbate three times weekly to gemcitabine/nab-paclitaxel was associated with substantially longer median overall and progression-free survival without detected worsening of quality of life or added toxicity.14 Other cancers have produced encouraging phase I/II findings, subgroup signals or negative results.
That pattern argues for a precision approach: identify the cancer biology, understand the treatment context, screen the patient carefully, define the objective and reassess the response.
Explore Physician-Directed Integrative Oncology
Is High-Dose IV Vitamin C Appropriate for Your Cancer Treatment Plan?
The answer depends on the cancer, treatment history, kidney function, G6PD status, current oncology regimen and the clinical objective. Our Patient Care Team can help you understand the next step.
Request a Cancer Consultation → Call 1-800-923-7878 Authorship, review and editorial method
How This Guide Was Prepared
Editorial and medical review
Written by: Sunridge Medical Editorial Team
Medical reviewer: Dr. Gioacchino Franco, NMD
Last medically reviewed: September 18, 2026
Evidence standards
We prioritize primary human trials, systematic reviews, PubMed-indexed papers and the National Cancer Institute. We identify study phase, sample size, comparison group, absolute results and important limitations. Laboratory and animal findings are labeled separately from human clinical evidence.
This page is educational and cannot determine whether treatment is appropriate for a specific patient. Decisions should be made with qualified clinicians who can review the diagnosis, oncology regimen, laboratory findings, kidney function, G6PD status and individual goals.
PRIMARY SOURCES & REVIEWS
References
- National Cancer Institute. Intravenous Vitamin C (PDQ®), Health Professional Version.
- Padayatty SJ, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. 2004. PMID 15068981.
- Chen Q, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide. PNAS. 2005.
- Chen Q, et al. Pharmacologic ascorbate generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. PNAS. 2007.
- Chen Q, et al. Pharmacologic ascorbate acts as a prooxidant and decreases aggressive tumor xenograft growth. PNAS. 2008.
- Monti DA, et al. Phase I evaluation of IV ascorbic acid with gemcitabine and erlotinib in metastatic pancreatic cancer. PLoS One. 2012.
- Welsh JL, et al. Pharmacological ascorbate with gemcitabine for metastatic and node-positive pancreatic cancer: phase I trial. 2013.
- Ma Y, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced chemotherapy toxicity. Sci Transl Med. 2014.
- Yun J, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015.
- Schoenfeld JD, et al. Pharmacologic ascorbate susceptibility in NSCLC and glioblastoma. Cancer Cell. 2017.
- Allen BG, et al. Phase I pharmacologic ascorbate with radiation and temozolomide for newly diagnosed glioblastoma. Clin Cancer Res. 2019.
- Furqan M, et al. Pharmacological ascorbate with platinum chemotherapy in advanced NSCLC. Redox Biol. 2022.
- Wang F, et al. VITALITY: high-dose vitamin C plus FOLFOX ± bevacizumab in metastatic colorectal cancer. Clin Cancer Res. 2022.
- Bodeker KL, et al. Randomized pharmacologic ascorbate, gemcitabine and nab-paclitaxel trial in metastatic pancreatic cancer. Redox Biol. 2024.
- Paller CJ, et al. High-dose IV vitamin C with docetaxel in metastatic castration-resistant prostate cancer: randomized phase II trial. 2024.
- Hoffer LJ, et al. Phase I clinical trial of IV ascorbic acid in advanced malignancy. Ann Oncol. 2008.
- Fritz H, et al. Intravenous Vitamin C and Cancer: A Systematic Review. Integr Cancer Ther. 2014.
- Qu J, et al. Overall and Progression-Free Survival Following Intravenous Vitamin C: Systematic Review and Meta-Analysis. 2025.
- Mikirova N, Hunninghake R. Effect of high dose vitamin C on Epstein-Barr viral infection. Med Sci Monit. 2014.
- Polireddy K, et al. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis. Sci Rep. 2017.
Living research library · positive published findingsOpen study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed →
Research organized by cancer type
Browse 21 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked cancer type to move directly to its corresponding Sunridge page.
Open study on PubMed →
Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.
Treatment with 100 μM VC significantly restored 5hmC levels in CR-BC cells by activating TET enzymes, inhibited cell proliferation, and enhanced cisplatin sensitivity; these effects were abrogated by the TET inhibitor Bobcat339, confirming VC acts in a TET-dependent manner.
Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin.
Co-treatment with ascorbate induced greater suppression of OS cell but not nonmalignant cell proliferation.
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
Treatment with buparlisib at lower doses, along with vitamin C, induced apoptosis and inhibited the growth of TNBC cells in vitro.
Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation.
Using Tet1/2/3-deficient mice and primary human acute myeloid leukemia (AML) models, we show that ATRA plus ascorbate more effectively induces differentiation, inhibits leukemia stem cell self-renewal in a TET2-dependent manner, and sensitizes AML cells to targeted therapies in vivo, leading to improved survival.
Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro.
Vitamin C (L-ascorbic acid, ascorbate, VC) is an important natural antioxidant, which has been reported to show suppressive effects in cancer treatment.
Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through Hydrogen-Peroxide-Induced-DNA-Damage.
Non-small cell lung cancer (NSCLC) poses a significant global health burden with unsatisfactory survival rates, despite advancements in diagnostic and therapeutic modalities.
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.
High-dose AA treatment synergized with anti-PD1 therapy in a syngeneic lymphoma mouse model, resulting in marked inhibition of tumor growth compared with either agent alone.
Ascorbate induces apoptosis in melanoma cells by suppressing Clusterin expression.
Here we show that 100 µM of ascorbate induced apoptosis in A2058 melanoma cells.
Vitamin C Sensitizes Melanoma to BET Inhibitors.
Cotreatment with ascorbate and JQ1 induced apoptosis and inhibited proliferation of cultured melanoma cells.
A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer.
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor 5-year survival.
Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism.
Phase I studies in pancreatic cancer (PDAC) utilizing P-AscH- have demonstrated increases in progression free survival, suggesting a reduction in metastatic disease burden.
Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer.
The current study demonstrates that pharmacologic ascorbate enhances the cytotoxic effects of ionizing radiation as seen by decreased cell viability and clonogenic survival in all pancreatic cancer cell lines examined, but not in nontumorigenic pancreatic ductal epithelial cells.
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.
The use of ascorbate, more commonly known as ascorbic acid or Vitamin C, has demonstrated antitumor activity in a variety of cancer cell types.
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.
There are several mechanisms currently under investigation to explain how ascorbate exerts anti-cancer effects.
Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis.
Compared with the treatment alone, the synthetic application of vitamin C (VitC, 800 μM) and ATO (1 μM) significantly further inhibited the proliferation, migration, and invasion of OS cells and promoted cell apoptosis in vitro.
Vitamin C induces ferroptosis in anaplastic thyroid cancer cells by ferritinophagy activation.
The present study demonstrated that vitamin C could significantly inhibit ATC cells growth through ferroptosis activation, evidenced by the GPX4 inactivation, ROS accumulation and iron-dependent lipid peroxidation.
High-dose Ascorbate Exhibits Anti-proliferative and Anti-invasive Effects Dependent on PTEN/AKT/mTOR Pathway in Endometrial Cancer in vitro and in vivo.
In this study, high-dose ascorbate significantly inhibited cell proliferation and invasion, increased cellular stress and DNA damage, and induced cell cycle arrest and apoptosis in EC cells.
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced chemotherapy toxicity.
In 27 women with stage III/IV ovarian cancer, IV ascorbate added to carboplatin/paclitaxel was associated with fewer grade 1 and 2 chemotherapy-related adverse events; the study was too small to establish a survival benefit.
Pharmacological ascorbate improves response to platinum-based chemotherapy in advanced NSCLC.
Among 38 evaluable patients receiving IV ascorbate with carboplatin/paclitaxel, the objective response rate was 34.2% and disease-control rate was 84.2%; randomized confirmation is needed.
Overall and progression-free survival following intravenous vitamin C: systematic review and meta-analysis.
IV vitamin C was associated with a pooled estimated median overall-survival ratio of 1.83. Heterogeneous designs and stronger effects in cohort studies limit causal conclusions.
No studies match those filters. Clear a filter or try a broader term.